Journal
JOURNAL OF NEUROSCIENCE
Volume 35, Issue 3, Pages 1136-1148Publisher
SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.1797-14.2015
Keywords
Amphotericin; innate immunity; macrophages; microglia; oligodendrocytes; remyelination
Categories
Funding
- NeuroScience Canada (Brain Repair Program)
- Scientific Foundation of the Multiple Sclerosis Society of Canada (MSSC)
- Alberta Innovates-Health Solutions (AIHS)
- MSSC
- AIHS
Ask authors/readers for more resources
Approaches to stimulate remyelination may lead to recovery from demyelinating injuries and protect axons. One such strategy is the activation of immune cells with clinically used medications, since a properly directed inflammatory response can have healing properties through mechanisms such as the provision of growth factors and the removal of cellular debris. We previously reported that the antifungal medication amphotericin B is an activator of circulating monocytes, and their tissue-infiltrated counterparts and macrophages, and of microglia within the CNS. Here, we describe that amphotericin B activates these cells through engaging MyD88/TRIF signaling. When mice were subjected to lysolecithin-induced demyelination of the spinal cord, systemic injections of nontoxic doses of amphotericin B and another activator, macrophage colony-stimulating factor (MCSF), further elevated the representation of microglia/macrophages at the site of injury. Treatment with amphotericin B, particularly in combination with MCSF, increased the number of oligodendrocyte precursor cells and promoted remyelination within lesions; these pro-regenerative effects were mitigated in mice treated with clodronate liposomes to reduce circulating monocytes and tissue-infiltrated macrophages. Our results have identified candidates among currently used medications as potential therapies for the repair of myelin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available